Oxford University

Contact information:

Oxford Motor Neuron Disease Care and Research Centre

Dr Kevin Talbot
Oxford University,
Department of Clinical Neurology,
3rd Floor, West Wing
John Radcliffe Hospital
Oxford, OX3 9DU, UK
Tel 44 1865 231904
Fax 44 1865 231885
[email protected]

ALS Clinic:

Neurosciences Outpatient Department
West Wing
John Radcliffe Hospital
John Radcliffe Hospital
Oxford, OX3 9DU, UK
www.oxfordmnd.net

Director: Dr Kevin Talbot
Assistant Director: Dr Martin Turner
Clinic Coordinator: Rachael Marsden

The Oxford Motor Neuron Disease Centre is based at the John Radcliffe Hospital in Oxford, UK and receives approximately 140 new referrals per year from all over South and Central England. We are funded by the UK MND Association and through other charitable sources and provide fully integrated care for patients with ALS and other motor neuron disorders. We are a major centre for research into ALS.

Research Lines:

  1. Genetics: Functional analysis of mutations in genes for ALS. Participation in large scale genome and sequencing studies.
  2. Cell biology of RNA processing in neurons with ALS and SMA in vitro and in vivo models
  3. Biomarkers: the BioMOx study is a longitudinal proteomics and imaging study of ALS patients
  4. Neuropathology: the Oxford Brain Bank has a large number of cases of ALS with good matched clinical data
  5. Clinical studies into the natural history of ALS. Participation in multicentre clinical trials.

Top 10 Publications:

  1. Bradley J. Turner, Steven Ackerley, Kay E. Davies, and Kevin Talbot. Dismutase-competent SOD1 mutant accumulation in myelinating Schwann cells is not detrimental to normal or transgenic ALS model mice. Hum Mol Genetics, published on line 23rd December 2009
  2. Dirk Bäumer, Sheena Lee, George Nicholson, Joanna Davies, Nicholas J. Parkinson, Lyndsay M. Murray, Thomas H. Gillingwater, Kay E. Davies and Kevin Talbot. Alternative splicing events are a late feature of pathology in a mouse model of Spinal Muscular Atrophy. PLoS Genetics, pub 18th Dec 2009.
  3. Murray LM, Lee S, Bäumer D, Parson SH, Talbot K, Gillingwater TH. Pre-symptomatic development of lower motor neuron connectivity in a mouse model of severe spinal muscular atrophy. Hum Mol Genet. 2010 Feb 1;19(3):420-33.
  4. Baumer D, Parkinson N, Talbot K. TARDBP in amyotrophic lateral sclerosis: identification of a novel variant but absence of copy number variation. J Neurol Neurosurg Psychiatry. 2009 Nov;80(11):1283-5.
  5. Turner MR, Brockington A, Scaber J, Hollinger H, Marsden R, Shaw PJ, Talbot K. Pattern of spread and prognosis in lower limb-onset ALS. Amyotroph Lateral Scler. [Epub ahead of print]
  6. Turner MR, Abisgold J, Yeates DG, Talbot K, Goldacre MJ. Head and other physical trauma requiring hospitalisation is not a significant risk factor in the development of ALS. J Neurol Sci. 2009 Oct 29. [Epub ahead of print] PubMed PMID:19878957.
  7. Talbot K. Another gene for ALS: mutations in sporadic cases and the rare variant hypothesis. Neurology. 2009 Oct 13;73(15):1172-3.
  8. Turner BJ, Parkinson NJ, Davies KE, Talbot K. Survival motor neuron deficiency enhances progression in an amyotrophic lateral sclerosis mouse model. Neurobiol Dis. 2009 Jun;34(3):511-7.
  9. Turner MR, Kiernan MC, Leigh PN, Talbot K. Biomarkers in amyotrophic lateral sclerosis. Lancet Neurol. 2009 Jan;8(1):94-109.
  10. Turner BJ, Bäumer D, Parkinson NJ, Scaber J, Ansorge O, Talbot K. TDP-43 expression in mouse models of amyotrophic lateral sclerosis and spinal muscular atrophy. BMC Neurosci. 2008 Oct 28;9:104.